Trevena Inc (TRVN.OQ)
TRVN.OQ on NASDAQ Stock Exchange Global Select Market
1.42USD
2:46pm EDT
1.42USD
2:46pm EDT
Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$1.42
$1.42
Open
$1.44
$1.44
Day's High
$1.44
$1.44
Day's Low
$1.39
$1.39
Volume
105,404
105,404
Avg. Vol
217,624
217,624
52-wk High
$3.00
$3.00
52-wk Low
$1.35
$1.35
About
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in... (more)
Overall
| Beta: | -0.53 |
| Market Cap(Mil.): | $97.20 |
| Shares Outstanding(Mil.): | 67.97 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TRVN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 214.53 | 33.05 |
| EPS (TTM): | -0.99 | -- | -- |
| ROI: | -82.82 | -3.67 | 13.17 |
| ROE: | -116.14 | -5.61 | 15.10 |
BRIEF-Trevena Appoints Mark Demitrack As Chief Medical Officer
* TREVENA APPOINTS MARK A. DEMITRACK, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:
BRIEF-Trevena Q1 Loss Per Share $0.14
* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S
BRIEF-Trevena Inc And Jiangsu Nhwa Pharmaceutical Announce License Agreement For Oliceridine In China
* TREVENA INC. AND JIANGSU NHWA PHARMACEUTICAL CO. LTD ANNOUNCE LICENSE AGREEMENT FOR OLICERIDINE IN CHINA
BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018
* TREVENA SAYS ON APRIL 9, ROBERTO CUCA, CHIEF FINANCIAL OFFICER OF CO FORMALLY NOTIFIED CO OF HIS RESIGNATION, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source text: (https://bit.ly/2GVszsP) Further company coverage:
BRIEF-Trevena Reports Q4 Loss Per Share $0.24
* COMPANY EXPECTS THAT EXPENSES WILL DECREASE IN 2018 COMPARED TO 2017
Estimates